NCT04854590已完成不适用
IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 248
- 试验地点
- 1
- 主要终点
- Incidence of febrile neutropenia (yes/no) and by severity (CTCAE grade)
研究概览
简要总结
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
详细描述
To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide.
排除标准
- •Patients who have no treatment history with the product (i.e.,durvalumab)
结局指标
主要结局
Incidence of febrile neutropenia (yes/no) and by severity (CTCAE grade)
时间窗: 16weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related CachexiaCachexiaPancreatic NeoplasmsNCT00060502Centocor, Inc.73
已完成
不适用
Towards optimizing infliximab therapy in severe sarcoidosis patients: personalized medicineSarcoidosisNL-OMON39486Sint Antonius Ziekenhuis52
招募中
不适用
Efficacy of tight control of Infliximab (IFX) for Crohn's disease (CD) by CRP value and fecal concentration of calprotectin (Quattro C study)Crohn's diseases diseaseJPRN-UMIN000011820ationalOrganizationHospital Fukuyama medical center15
招募中
不适用
EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMABInflammatory Bowel DiseasesRheumatologic DiseaseNCT05719389IRCCS San Raffaele250
已完成
1 期
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid TumorsNeoplasmsMalignanciesNCT02257476Emory University22